Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Terumo Acquires 5% of Fuji Pharma To Grow Drug/Device Combo Product Business

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Japanese device maker Terumo Corp. reached an agreement to purchase 5 percent of Fuji Pharma common shares for jointly developing a drug and device combination product business in Japan - the first such convergence undertaking in a country where the government in the past administered the pharmaceutical and medical device markets almost separately

You may also be interested in...

Terumo To Launch New Blood Pressure Monitor Targeted At Females

Japanese medical device maker Terumo announced Jan. 8 that the company plans a February launch of Premiage P400, a blood pressure monitor that is applied on the wrist. According to the company, the device will be targeted at females in their 50s who are most likely to develop lifestyle diseases such as hypertension. Priced at around ¥10,000, the product also comes in four colors, including pink and beige. (Click here for more - Japanese language

Terumo To Expand Cerebral Aneurysm Device Sales In The U.S., Other Markets

TOKYO - Terumo plans to expand its product line of cerebral aneurysm and other brain treatment devices in the U.S. and overseas markets with hopes of reaching ¥10 billion ($992 million) in cerebral aneurism device sales by March 2011, Terumo said Sept. 3

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts